其他免疫抑制剂
已有使用利妥昔单抗成功治疗难治性/复发性疾病患者的病例报告,[19]Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002;61:922-924.http://www.ncbi.nlm.nih.gov/pubmed/12228164?tool=bestpractice.com也有用霉酚酸成功治疗的病例报告。[20]Kiykim AA, Horoz M, Gok E. Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid. Intern Med. 2010;49:577-580.https://www.jstage.jst.go.jp/article/internalmedicine/49/6/49_6_577/_articlehttp://www.ncbi.nlm.nih.gov/pubmed/20228594?tool=bestpractice.com
蛋白A免疫吸附
抗体与蛋白A非常紧密的结合。通过将蛋白A柱添加到血浆置换循环中,从理论上讲可以很快清除大量的免疫球蛋白。但是,如果是用免疫吸附替代血浆置换,血浆置换疗法清除其它炎症介质的潜在优势就会丢失。[1]Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64:1535-1550.http://www.ncbi.nlm.nih.gov/pubmed/12969182?tool=bestpractice.com[21]Hu W, Liu Z, Ji D, et al. Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol. 2006;19:312-317.http://www.ncbi.nlm.nih.gov/pubmed/16874690?tool=bestpractice.com[22]Bygren P, Freiburghaus C, Lindholm T, et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet. 1985;2:1295-1296.http://www.ncbi.nlm.nih.gov/pubmed/2866351?tool=bestpractice.com尚不清楚这种疗法具有任何超过血浆置换的优势。